Evidence map›Paper›PMID 37736271›Full record

ArticleAmerican journal of stem cells2023

Upregulation of C-X-C chemokine receptor type 4 (CXCR4) in the breast cancer stem like cells.

Mohammad Kamalabadi-Farahani, Vahid Kia, Shaghayegh Doodi, Sadegh Dylami

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of stem cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mohammad Kamalabadi-FarahaniDepartment of Tissue Engineering, School of Medicine, Shahroud University of Medical Sciences Shahroud, Iran.
Vahid KiaDepartment of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences Shahroud, Iran.
Shaghayegh DoodiStudent Research Committee, School of Medicine, Shahroud University of Medical Sciences Shahroud, Iran.
Sadegh DylamiStudent Research Committee, School of Medicine, Shahroud University of Medical Sciences Shahroud, Iran.
Shahroud University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesBreast cancer stem like cells (CSCs) as a subset of cancer cells exhibit similar properties with normal stem cells. These cells are responsible for cancer metastasis and recurrence. Pivotal roles of CXCR4 in metastasis, chemoresistance and stemness of tumor cells have been showed previously. Here, we aim to explore the relationship between CXCR4 and CSCs in primary and metastatic breast tumor cells. METHODS AND

resultsPrimary and highly metastatic breast tumor cells were isolated in our laboratory. Spheroid formation was used to confirm the presence of CSCs and their self-renewal capability. CXCR4 expression was evaluated using real-time polymerase chain reaction in monolayer culture and multicellular spheroids. Our data showed that in all tested cells, CXCR4 expression was significantly increased in CSCs. In parallel, compared with primary tumor cells, downregulation of CXCR4 in metastatic tumor cells was confirmed.

conclusionThese results provided new insights related to significant alteration of CXCR4 expression in multicellular spheroids. Analysis of molecular properties of spheroids could be used to detect molecular and genetic aspects of CSCs and also created a targeted therapeutic strategy against breast CSCs.

Indexed as

Breast cancercancer stem cellsCXCR4metastasismulticellular spheroids

Identifiers

PMID37736271
PMCPMC10509503
OpenAlexW4386945412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.